Fig. 3: UCART123 treatment results in long-term survival of primary BPDCN PDX. | Nature Communications

Fig. 3: UCART123 treatment results in long-term survival of primary BPDCN PDX.

From: Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Fig. 3

a Experimental design. NSGS mice were injected intravenously with 2 × 106 cells from BPDCN-1 (68.4% CD123+) at day 0. Engraftment was confirmed by analysis of peripheral blood on Day 21 post tumor cell injection, mice were divided randomly into 4 treatment groups (n = 9–10 mice/group) and received treatment as follows: vehicle; 10 × 106 TCRαβ KO T cells; 3 × 106 UCART123 cells; or 10 × 106 UCART123 cells via single tail vein injection. b Survival of the mice in indicated treatment groups was estimated by the Kaplan-Meier method. Treatment with UCART123 resulted in significant survival extension. MST = median survival time (in days). Significance was determined using unpaired two-tailed t-test annotated as “NS” (not significant, p ≥ 0.05), *P ≤  0.05, ***P ≤  0.001. c Circulating tumor burden was measured by flow cytometry in peripheral mouse blood samples collected on the indicated days (post treatment). Presence of human tumor cells was analyzed using cell surface expression of hCD123 among (DAPI-) viable cells. Source data are provided as a Source data file.

Back to article page